KCM
IBB icon

Kanawha Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Kanawha Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
10,517
+704
+7% +$121K 0.13% 103
2026
Q1 		$1.66M Buy
9,813
+449
+5% +$76.8K 0.12% 103
2025
Q4 		$1.58M Buy
9,364
+519
+6% +$84.3K 0.11% 101
2025
Q3 		$1.28M Buy
8,845
+78
+0.9% +$10.6K 0.09% 109
2025
Q2 		$1.11M Buy
8,767
+124
+1% +$15.2K 0.08% 112
2025
Q1 		$1.11M Sell
8,643
-296
-3% -$40.1K 0.09% 111
2024
Q4 		$1.18M Buy
8,939
+555
+7% +$78K 0.09% 108
2024
Q3 		$1.22M Buy
8,384
+1,432
+21% +$207K 0.09% 116
2024
Q2 		$954K Buy
6,952
+2,705
+64% +$361K 0.07% 126
2024
Q1 		$583K Buy
4,247
+970
+30% +$132K 0.05% 152
2023
Q4 		$445K Buy
3,277
+375
+13% +$45.8K 0.04% 157
2023
Q3 		$355K Sell
2,902
-40
-1% -$5.09K 0.03% 164
2023
Q2 		$374K Buy
2,942
+40
+1% +$5.2K 0.03% 160
2023
Q1 		$375K Buy
2,902
+140
+5% +$18.3K 0.04% 162
2022
Q4 		$363K Sell
2,762
-25
-0.9% -$3.23K 0.04% 164
2022
Q3 		$326K Buy
2,787
+45
+2% +$5.59K 0.04% 158
2022
Q2 		$323K Buy
2,742
+5
+0.2% +$594 0.03% 162
2022
Q1 		$357K Buy
2,737
+57
+2% +$7.42K 0.03% 167
2021
Q4 		$409K Hold
2,680
– – 0.03% 159
2021
Q3 		$433K Hold
2,680
– – 0.04% 152
2021
Q2 		$439K Buy
2,680
+25
+0.9% +$3.85K 0.04% 157
2021
Q1 		$400K Hold
2,655
– – 0.04% 156
2020
Q4 		$402K Hold
2,655
– – 0.04% 154
2020
Q3 		$360K Hold
2,655
– – 0.04% 155
2020
Q2 		$363K Sell
2,655
-171
-6% -$21.8K 0.04% 151
2020
Q1 		$304K Hold
2,826
– – 0.04% 151
2019
Q4 		$341K Buy
+2,826
New +$315K 0.04% 157

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Kanawha Capital Management's IBB Position: Q2 2026 in Review

Kanawha Capital Management increased its iShares Biotechnology ETF (IBB) stake by 7.2% in Q2 2026, buying an estimated $121K and bringing the position to 10,517 shares worth $2M. The position accounts for 0.13% of the portfolio, ranked #103.

Kanawha Capital Management first reported a position in IBB in Q4 2019 and has held it in 27 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Kanawha Capital Management held 10,517 shares of iShares Biotechnology ETF worth $2M as of Q2 2026.
  • Kanawha Capital Management bought 704 iShares Biotechnology ETF shares in Q2 2026, an estimated $121K.
  • iShares Biotechnology ETF made up 0.13% of Kanawha Capital Management's portfolio in Q2 2026, its #103 holding.
  • Kanawha Capital Management first reported a position in iShares Biotechnology ETF in Q4 2019 and has held it in 27 quarters since.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Kanawha Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.